Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | May 25, 2010 | May 27, 2010 |
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 03, 2022 | May 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date May 25, 2010 · Filed May 27, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 99,279 |
Reported balance
After 2010-05-25 transaction · row 1
1 source rowRow 1 · 2010-05-25 · Gift · Disposed 555 · Balance 99,279 |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy daughter | 1,643 |
Reported balance
After 2010-05-25 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2010-05-25 · Gift · Acquired 555 · Balance 1,643 F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 18,758 |
Reported balance
Holding disclosure · report date 2010-05-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 18,758 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of May 26, 2010. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy wife | 36,407 |
Reported balance
Holding disclosure · report date 2010-05-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 36,407 F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of May 26, 2010.
F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter.
BAXTER INTERNATIONAL INC
Report date May 03, 2022 · Filed May 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 15,740 |
Reported balance
After 2022-05-03 transaction · row 1
1 source rowRow 1 · 2022-05-03 · Grant · Acquired 2,706 · Balance 15,740 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. |
| Common Stock, $1 par valueSEC Table I · non-derivative | IndirectShares Owned by Thomas F. Chen Grantor Irrevocable Trust | 9,174 |
Reported balance
Holding disclosure · report date 2022-05-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,174 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STERICYCLE INC
Report date November 04, 2024 · Filed November 04, 2024
Section 16 reporting ended · disclosed 2024-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 1
1 source rowRow 1 · 2024-11-04 · Disposition to issuer · Disposed 20,303 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of June 3, 2024 (the "Merger Agreement"), by and among Stericycle, Inc. (the "Company"), Waste Management, Inc. and Stag Merger Sub Inc., at the effective time (the "Effective Time") of the merger of Stag Merger Sub Inc. with and into the Company, which Effective Time occurred on November 4, 2024, each outstanding share of Company common stock was converted into the right to receive $62.00 per share in cash, without interest. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $138.45 · Expires 2025-05-27 | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-04 · Disposition to issuer · Disposed 4,931 · Balance 0 F2: This stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was fully vested and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (without interest) an amount of cash equal to the product of (i) the number of shares underlying the stock option multiplied by (ii) the excess, if any, of $62.00 over the exercise price of such stock option. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.47 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-04 · Disposition to issuer · Disposed 3,713 · Balance 0 F2: This stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was fully vested and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (without interest) an amount of cash equal to the product of (i) the number of shares underlying the stock option multiplied by (ii) the excess, if any, of $62.00 over the exercise price of such stock option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-04 · Disposition to issuer · Disposed 3,524 · Balance 0 F3: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock. F4: Represents RSUs that would have vested in full on the earlier of the one-year anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders, provided that the date of the 2025 Annual Meeting of Stockholders had been at least 50 weeks after the date of the 2024 Annual Meeting of Stockholders. Pursuant to the Merger Agreement, at the Effective Time, these RSUs were canceled and converted into the right to receive (without interest) an amount in cash equal to the number of RSUs multiplied by $62.00. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-04 · Disposition to issuer · Disposed 1,506 · Balance 0 F3: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock. F5: Represents RSUs that were fully vested prior to the Effective Time, but, in accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person previously elected to defer actual receipt of the shares to which such person would otherwise have been entitled upon vesting until such person's separation of service from the issuer. Pursuant to the Merger Agreement, at the Effective Time, these RSUs were canceled and converted into the right to receive (without interest) an amount in cash equal to the number of RSUs multiplied by $62.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of June 3, 2024 (the "Merger Agreement"), by and among Stericycle, Inc. (the "Company"), Waste Management, Inc. and Stag Merger Sub Inc., at the effective time (the "Effective Time") of the merger of Stag Merger Sub Inc. with and into the Company, which Effective Time occurred on November 4, 2024, each outstanding share of Company common stock was converted into the right to receive $62.00 per share in cash, without interest.
F2: This stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was fully vested and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (without interest) an amount of cash equal to the product of (i) the number of shares underlying the stock option multiplied by (ii) the excess, if any, of $62.00 over the exercise price of such stock option.
F3: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock.
F4: Represents RSUs that would have vested in full on the earlier of the one-year anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders, provided that the date of the 2025 Annual Meeting of Stockholders had been at least 50 weeks after the date of the 2024 Annual Meeting of Stockholders. Pursuant to the Merger Agreement, at the Effective Time, these RSUs were canceled and converted into the right to receive (without interest) an amount in cash equal to the number of RSUs multiplied by $62.00.
F5: Represents RSUs that were fully vested prior to the Effective Time, but, in accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person previously elected to defer actual receipt of the shares to which such person would otherwise have been entitled upon vesting until such person's separation of service from the issuer. Pursuant to the Merger Agreement, at the Effective Time, these RSUs were canceled and converted into the right to receive (without interest) an amount in cash equal to the number of RSUs multiplied by $62.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,776 | $52.49 | $93,222.24 |
DisclosureSEC source: 0001104659-07-012363 · a4.xml · nonDerivative · entry 6 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,716 Read SEC document |
| February 18, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 684 | $52.49 | $35,903.16 |
DisclosureSEC source: 0001104659-07-012363 · a4.xml · nonDerivative · entry 5 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,492 Read SEC document |
| February 17, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,644 | $52.49 | $86,293.56 |
DisclosureSEC source: 0001104659-07-012363 · a4.xml · nonDerivative · entry 4 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,176 Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,000 | $0.00 Strike: $52.54 | $0.00 |
DisclosureSEC source: 0001104659-07-012363 · a4.xml · derivative · entry 10 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: common shares · 83,000 shares Expires 2017-02-15 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 27,667 on 02/16/2008, 27,667 on 02/16/2009, and 27,666 on 02/16/2010. Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,000 | $52.54 | $893,180.00 |
DisclosureSEC source: 0001104659-07-012363 · a4.xml · nonDerivative · entry 3 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,820 F2 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 1996 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,400 | $52.54 | $1,071,816.00 |
DisclosureSEC source: 0001104659-07-012363 · a4.xml · nonDerivative · entry 2 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,820 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,101 | $52.70 | $374,222.70 |
DisclosureSEC source: 0001104659-07-012363 · a4.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,420 Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 17,274 | $0.00 Strike: $52.66 | $0.00 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · derivative · entry 15 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,274 Underlying: common shares · 17,274 shares Expires 2010-02-10 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 17,965 | $0.00 Strike: $52.66 | $0.00 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · derivative · entry 14 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,965 Underlying: common shares · 17,965 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,701 | $0.00 Strike: $44.96 | $0.00 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · derivative · entry 13 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 2,701 shares Expires 2007-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,137 | $0.00 Strike: $39.72 | $0.00 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · derivative · entry 12 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 5,137 shares Expires 2007-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 20,339 | $0.00 Strike: $41.14 | $0.00 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · derivative · entry 11 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98 Underlying: common shares · 20,339 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 21,281 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · derivative · entry 10 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,639 Underlying: common shares · 21,281 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,838 | $53.11 | $416,299.69 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · nonDerivative · entry 6 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,521 Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 35,239 | $52.66 | $1,855,685.74 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · nonDerivative · entry 5 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,359 Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,701 | $44.96 | $121,436.96 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · nonDerivative · entry 4 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,137 | $39.72 | $204,021.09 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · nonDerivative · entry 3 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 20,339 | $41.14 | $836,837.99 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · nonDerivative · entry 2 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2007 Filed Feb 2, 2007 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 21,281 | $41.03 | $873,195.61 |
DisclosureSEC source: 0001104659-07-006576 · a4.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2006 Filed Aug 12, 2008 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 461 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-08-052315 · a4.xml · nonDerivative · entry 6 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 2,937 Read SEC document |
| October 03, 2006 Filed Aug 12, 2008 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 461 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-08-052315 · a4.xml · nonDerivative · entry 2 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,107 Read SEC document |
| April 24, 2006 Filed Apr 26, 2006 21:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 47,000 | $0.00 Strike: $41.48 | $0.00 |
DisclosureSEC source: 0001104659-06-027990 · a4.xml · derivative · entry 5 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: common shares · 47,000 shares Expires 2016-04-23 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 15,667 on 4/24/07, 15,667 on 4/24/08 and 15,666 on 4/24/09. Read SEC document |
| April 24, 2006 Filed Apr 26, 2006 21:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,000 | $41.48 | $580,720.00 |
DisclosureSEC source: 0001104659-06-027990 · a4.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,140 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.